Gusacitinib hydrochloride is under clinical development by Libertas Bio and currently in Phase II for Atopic Dermatitis (Atopic Eczema). According to GlobalData, Phase II drugs for Atopic Dermatitis (Atopic Eczema) have a 31% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Gusacitinib hydrochloride’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Gusacitinib hydrochloride overview
Gusacitinib hydrochloride (ASN-002) is under development for the treatment of hand dermatitis, atopic dermatitis, chronic dermatitis and systemic lupus erythematosus. The drug candidate is administered orally as a tablet. The drug candidate acts by targeting spleen tyrosine kinase (SYK) and Janus kinase (JAK).
See Also:
The drug candidate was also under development for the treatment of rheumatoid arthritis, relapsed/refractory non-Hodgkin lymphomas including follicular lymphoma, diffuse large B-cell lymphoma, mantle cell lymphoma, chronic lymphocytic leukemia, myelofibrosis, multiple myeloma, erythroleukemia, bladder cancer and Peripheral T-Cell Lymphomas (PTCL).
For a complete picture of Gusacitinib hydrochloride’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
